Patents by Inventor Justin R. Fallon

Justin R. Fallon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230304012
    Abstract: Methods and compositions for increasing muscle regeneration and for preventing or treating diseases, disorders or conditions associated with neuromuscular dysfunction, are provided herein.
    Type: Application
    Filed: October 16, 2020
    Publication date: September 28, 2023
    Inventors: Justin R. FALLON, Laura A. MADIGAN, Ashley E. WEBB, Beth MCKECHNIE, Lauren FISH, Diego JAIME, John PAGE
  • Publication number: 20220193114
    Abstract: Methods and compositions for increasing neurogenesis and for preventing or treating diseases, disorders or conditions associated with neurodegeneration, are provided herein.
    Type: Application
    Filed: April 17, 2020
    Publication date: June 23, 2022
    Inventors: Justin R. FALLON, Ashley E. WEBB, Beth McKECHNIE, Tali SORETS, Lauren FISH, Diego JAIME, John PAGE
  • Publication number: 20180327469
    Abstract: The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Application
    Filed: May 10, 2018
    Publication date: November 15, 2018
    Inventors: Justin R. Fallon, Alison R. Amenta, Beth A. McKechnie, Michelle Dechene, Atilgan Yilmaz
  • Patent number: 9969785
    Abstract: The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: May 15, 2018
    Assignee: Brown University
    Inventors: Justin R. Fallon, Alison R. Amenta, Beth A. McKechnie, Michelle Dechene, Atilgan Yilmaz
  • Patent number: 9958458
    Abstract: The present disclosure provides methods for predicting a patient's response to biglycan therapy for diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of such diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. This application also provides combination therapeutics, such as a biglycan therapeutic and a utrophin therapeutic.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: May 1, 2018
    Assignee: Brown University
    Inventors: Alison R. Amenta, Atilgan Yilmaz, Beth A. McKechnie, Justin R. Fallon
  • Publication number: 20150182589
    Abstract: The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.
    Type: Application
    Filed: August 29, 2014
    Publication date: July 2, 2015
    Inventors: Justin R. Fallon, Michael Rafii, Mark A. Bowe, Beth A. McKechnie, Alison R. Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Patent number: 8822418
    Abstract: The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: September 2, 2014
    Assignee: Brown University
    Inventors: Justin R. Fallon, Michael Rafii, Mark A. Bowe, Beth McKechnie, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Patent number: 8691766
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: April 8, 2014
    Assignee: Brown University Research Foundation
    Inventors: Justin R. Fallon, Beth A. McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison R. Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Patent number: 8658596
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: February 25, 2014
    Assignee: Brown University Research Foundation
    Inventors: Justin R. Fallon, Mark A. Bowe, Beth McKechnie, Michael Rafii, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Publication number: 20140038906
    Abstract: The present disclosure provides methods for predicting a patient's response to biglycan therapy for diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of such diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. This application also provides combination therapeutics, such as a biglycan therapeutic and a utrophin therapeutic.
    Type: Application
    Filed: December 27, 2011
    Publication date: February 6, 2014
    Applicant: BROWN UNIVERSITY
    Inventors: Alison R. Amenta, Atilgan Yilmaz, Beth A. McKechnie, Justin R. Fallon
  • Publication number: 20120245095
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Application
    Filed: February 8, 2012
    Publication date: September 27, 2012
    Applicant: Brown University Research Foundation
    Inventors: Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Patent number: 8138154
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: March 20, 2012
    Assignee: Brown University Research Foundation
    Inventors: Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Publication number: 20120004178
    Abstract: The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Application
    Filed: May 17, 2011
    Publication date: January 5, 2012
    Inventors: Justin R. Fallon, Alison R. Amenta, Beth A. McKechnie, Michelle Dechene, Atilgan Yilmaz
  • Publication number: 20110183910
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Application
    Filed: September 14, 2010
    Publication date: July 28, 2011
    Applicant: Brown University Research Foundation
    Inventors: Justin R. Fallon, Mark A. Bowe, Beth McKechnie, Michael Rafii, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Publication number: 20110053854
    Abstract: The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.
    Type: Application
    Filed: May 24, 2010
    Publication date: March 3, 2011
    Inventors: Justin R. Fallon, Michael Rafii, Mark A. Bowe, Beth McKechnie, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Patent number: 7816322
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: October 19, 2010
    Assignee: Brown University Research Foundation
    Inventors: Justin R. Fallon, Mark A. Bowe, Beth McKechnie, Michael Rafii, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Patent number: 7759314
    Abstract: The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: July 20, 2010
    Assignee: Brown University
    Inventors: Justin R. Fallon, Michael Rafii, Alison Amenta, Mark Bowe, Beth McKechnie, Mary Lynn Mercado, Hiroki Hagiwara
  • Publication number: 20100130405
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Application
    Filed: July 6, 2009
    Publication date: May 27, 2010
    Applicant: Brown Technology Partnerships
    Inventors: Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Raymond Ferri, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Patent number: 7612038
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: November 3, 2009
    Assignee: Brown University
    Inventors: Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Publication number: 20080274966
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Application
    Filed: February 22, 2008
    Publication date: November 6, 2008
    Applicant: Brown University Research Foundation
    Inventors: Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Raymond Ferri